ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 915 in its research report dated February 08, 2019.
Aurobindo has maintained its guidance of 30 percent YoY growth in injectable sales. Further, company filed 10 ANDAs, including 4 injectables, taking the cumulative ANDAs pending for approval to 122
The company had inked a binding agreement on July 14, 2018, to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorisations and dossier licence rights in Poland, the Czech Republic, the Netherlands, Spain and Belgium, Aurobindo Pharma said in a regulatory filing.
The rise net profit was aided by strong performance of US, Europe, emerging markets and active pharmaceutical ingredients business. Favorable foreign exchange too added to the profit.
Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 940 in its research report dated January 17, 2019.
Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.
Commenting on the filing targets, Aurobindo said it plans to file all products over next 3 years in the oncology and hormones segment.
For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.
Most experts are of the view that as long as Nifty holds above 10800-10850, bulls should remain in charge of D-Street.
The voluntary recall of Amlodipine Valsartan tablets USP, Valsartan HCTZ tablets USP and Valsartan tablets USP to the consumer level is due to the detection of trace amounts of an unexpected impurity found in the finished drug product, according to a release by the company posted on the website of the US Food and Drug Administration (USFDA).
Harendra Kumar of Elara Capital said given the overall robustness in earnings recovery, 2019 could well be a year of midcaps and smallcaps.
This is the verbatim transcript of Aurobindo Pharma management call with analysts.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Vecuronium Bromide Injection in the strengths of 10mg and 20mg, Aurobindo Pharma said in a BSE filing.
Aurobindo Pharma said Vecuronium Bromide will be launched in Q4FY19.
The breadth of the market favoured the advances with 764 stocks advancing and 913 declining while 384 remained unchanged. On the BSE, 1157 stocks advanced, 1297 declined and 142 remained unchanged.
The latest lawsuit is a part of growing litigation against the makers and distributors of sartan-based blood pressure lowering drugs in the US, the report said.
In coming week any tick above 9,350 on Nifty Pharma index will trigger fresh buying in pharma stocks, Arpan Shah of Monarch Networth Capital said
A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company
The slowdown in production at Morgantown site could provide a window of opportunity to Mylan's peers
The company is also planning to launch first set of biosimilars and vaccines in growth markets during this time, Aurobindo Pharma said in an investor presentation.
HDFC Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 875 in its research report dated November 14, 2018.
Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 909 in its research report dated November 13, 2018.
Aurobindo Pharma has said it's wholly-owned subsidiaryhas entered into an agreement to acquire a product under development and related assets from Australia-based Advent Pharmaceuticals Pty Ltd for USD 12.5 million.